Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non-infected control subjects Clear all

Conditions: HIV
Interventions: Rifaximin, Placebo; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Bethesda, Maryland • Pittsburgh, Pennsylvania

Conditions: HIV
Interventions: HIV positive subjects, Non-infected control subjects; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: HIV Infections
Interventions: raltegravir; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 8
States / cities: Anaheim, California • Hayward, California • Los Angeles, California + 4 more

Conditions: Malaria
Interventions: PfSPZ Vaccine, CHMI (7G8), CHMI (NF135.C10); Biological
Lead sponsor: Sanaria Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Silver Spring, Maryland

Conditions: HIV Infection
Interventions: Polyphenon E, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Open Chest Wounds
Interventions: Wound Vacuum-assisted dressing, Control group; Device · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: HIV Infection
Interventions: Vitamin D3 50,000 IU, Vitamin D3 placebo; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 24 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 16
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 11 more

Conditions: Malaria
Interventions: GSK257049 Dosage 1, GSK257049 Dosage 2, Sporozoite-infected mosquitoes challenge; Biological · Procedure
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: HIV-1 Infection, HIV Infections
Interventions: mRNA-transfected autologous dendritic cells, autologous dendritic cells with no mRNA transfection; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Virus Diseases, HIV
Interventions: Switch NRTIs as a Backbone to Raltegravir; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: HIV
Interventions: MBSR Course, HEP Course; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 45 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Pancreatitis, Acute Necrotizing
Interventions: meropenem; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 9
States / cities: San Francisco, California • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: Diabetic Foot Ulcer
Interventions: BR-AC, Standard Care; Other
Lead sponsor: BioStem Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 11
States / cities: San Francisco, California • Sylmar, California • Torrance, California + 8 more

Conditions: Bacteremia
Interventions: No intervention; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 1,354 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetic Foot Ulcer
Interventions: NOX1416 and SOC, SOC (Standard of care); Drug · Procedure
Lead sponsor: NOxy Health Products, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Phoenix, Arizona • Tucson, Arizona • Coral Gables, Florida + 9 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: JNJ-53718678 500 mg, JNJ-53718678 80 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 13
States / cities: Cerritos, California • Chula Vista, California • Garden Grove, California + 10 more

Conditions: HIV Infections
Interventions: Racivir, a non-nucleoside reverse transcriptase inhibitor; Drug
Lead sponsor: Pharmasset; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 3
States / cities: Chicago, Illinois • The Bronx, New York • Columbia, South Carolina

Conditions: HIV Infections
Interventions: Optimized Background Therapy (OBT), maraviroc (UK-427,857); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 16 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 31 more

Conditions: Cystic Fibrosis
Interventions: azithromycin 250 mg tablets, placebo tablets; Drug
Lead sponsor: CF Therapeutics Development Network Coordinating Center; Network
Eligibility: 6 Years to 18 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 31
States / cities: Phoenix, Arizona • Hartford, Connecticut • Atlanta, Georgia + 27 more

Conditions: Hepatitis C Infection, Thrombocytopenia
Interventions: romiplostim, ribavirin, placebo, PEG-interferon alfa-2a, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Malaria
Interventions: RTS,S/AS01E, RTS,S/AS01B, Sporozoite-infected mosquitoes challenge.; Biological · Procedure
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Malaria
Interventions: Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01), GSK Biologicals' malaria vaccine 257049 (2 doses), GSK Biologicals' malaria vaccine 257049 (3 doses), Sporozoite challenge; Biological · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Diabetic Foot Infection, Diabetic Foot
Interventions: Topical Pravibismane, Standard of Care; Drug · Other
Lead sponsor: Microbion Corporation; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Fresno, California • Dallas, Texas • McAllen, Texas + 1 more

Conditions: HIV Infection
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

Rifaximin for Chronic Immune Activation in People With HIV

Selection of a Protective T Cell-based HIV-1/FIV Vaccine

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects

PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults

Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals

Vacuum-Assisted Dressings (V-AD) in the Management of Open Chest Wounds

Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART

Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults

A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects

A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen

Effects of Mindfulness Training on Chronic Inflammation in HIV-Infected Adults

A Study to Determine if Antibiotics Prevent Infection in the Pancreas of Patients Where Part of the Pancreas Has Died

A Prospective Trial of Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AC

Virulence Determinants in S Aureus Bacteremia

NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers

A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects

Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults

Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients

Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People